Innovative preclinical studies for gastrointestinal diseases

Enterosys is a CRO scientifically rooted in the gut

In addition to the digestive function, the gut is a barrier that allows the transport of essential micronutrients for our cells and stops deleterious substances and toxins: this is the barrier function.

The intestinal microbiota participates in digestion and interacts with the body’s immune system. These billions of microorganisms are involved in the maintenance of good health of the body but also in the development of various pathologies when the balance of the intestinal flora is altered leading to a phenomenon named dysbiosis.

The gut and the flora it harbors represent so many molecules with potential therapeutic or wellbeing interest. This is our real inner pharmacy! Enterosys proposes smart and innovative solutions to develop and valorize your own leads.

Disorders & diseases interacting with the gut and Gut brain

AGING

The role of the gut microbiota in human aging is important because directly impacts aging through the gastrointestinal system and enteric neurons viability.

CHRONIC CONSTIPATION (CC)

The main mechanisms discussed were colonic sensorimotor dysfunction and alteration of the gut microbiota. However, the pathogenesis of CC is multifactorial and includes colonic motility and fluid transport, anorectal movement, and sensory functions, as well as dietary and behavioral factors

DIARRHEA

is a clinical manifestation of intestinal ion transport channel proteins, channels, physical and chemical barriers being damaged, leading to disorders of water and electrolyte transport in the digestive tract. It is a common problem to the whole world and the occurrence of diarrhea is highly associated with gut microbiota

ENTERIC NEUROPATHIES

emanate from loss, degeneration, and/or functional impairment of enteric nervous system (ENS). They are caused by congenital defects in ENS development, acquired through the effect of infectious agents or toxins, or secondary to other pathological conditions such as diabetes and neurodegenerative disorders.

IRRITABLE BOWEL DISEASES (IBD)

is a collective term used to describe prolonged inflammation of the gastrointestinal tract, primarily include Crohn’s disease (CD), which can present throughout the entire gastrointestinal tract, and ulcerative colitis (UC), presenting in the mucosal layer of the colon.
IBD is identified as an immune pathology and is believed to develop through interactions between environmental, microbial, and immune-mediated factors in a genetically predisposed host.

IRRITABLE BOWEL SYNDROME (IBS)

is a chronic functional gastrointestinal disorder and one of the most prevalent gastrointestinal diseases. The pathogenesis of IBS is multifactorial, includes genetic, physiological, psychosocial, and environmental factors

« LEAKY GUT » PHENOTYPE

Some fragments of food, bacteria or viruses pass through the open tight junctions of the intestinal barrier into the bloodstream causing: inflammation, immune reactions and autoimmune diseases, nutrient deficiencies and passage through the blood-brain barrier causing cascading reactions throughout the body.

At the cutting edge of preclinical studies in gastrointestinal disease

Thanks to our different innovative approaches, we propose solutions to study all parameters to characterize the leaky gut phenotype and the effects of your active compounds on the intestinal permeability and gut barrier function.

Figure from Abot A, Fried S, Cani PD, Knauf C. Reactive Oxygen Species/Reactive Nitrogen Species as Messengers in the Gut: Impact on Physiology and Metabolic Disorders. Antioxid Redox Signal. 2021 Dec 31. doi: 10.1089/ars.2021.0100. Epub ahead of print. PMID: 34714099.

Discover our preclinical models

Enterosys offers you a complete and innovative offer of preclinical protocols based on in vitro and in vivo efficacy tests.

Discover our approach

Our experience in R&D allows us to meet your objectives and offer you support for the design and development of new models, guided by our innovation management approach.

Discover our preclinical models

Enterosys offers you a complete and innovative offer of preclinical protocols based on in vitro and in vivo efficacy tests.

Discover our approach

Our experience in R&D allows us to meet your objectives and offer you support for the design and development of new models, guided by our innovation management approach.

Gut & gut-organs communication: major role in many disorders and diseases

NEURODEGENERATIVE DISEASES

METABOLIC
DISEASES

DERMATOLOGICAL DISEASES

Question about the contribution of Gut and Gut-organs axis to your preclinical studies and innovation portfolio ?

Our team of experts will be happy to answer all your questions and discuss with you to guide you in the design of an optimized protocol to meet your objectives and add value to your molecules with quick and concrete solutions.